Immune checkpoint inhibitors have revolutionized treatment of non-small cell lung cancer. In this study, breath prophiles were collected from 143 patients and a single biomarker profile was created that detected responses to anti-PD-1 treatment with 89% accuracy.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Other
Prediction of Response to Anti-PD-1 Therapy in Patients With Non-small-cell Lung Cancer by Electronic Nose Analysis of Exhaled Breath
September 20, 2019
August 22, 2019
This study of over 25,000 pts from the International Lung Cancer Consortium identified underweight and severly obese patients as having poorer survival than others, whereas a survival advantage was evident among patients who were overweight or mildly obese. Decreased BMI (wt loss) was associated with poorer outcomes across all BMI categories.
August 21, 2019
An interesting discussion in this manuscript of a case-control study of 666 subjects.
August 20, 2019
Interesting follow-up study of 208 pulmonary ground -glass opacities in 160 subjects, with a yield of three adenocardinomas.
In Global News: Expanded MitraClip Indications, Congenital Heart Surgery After Fukushima Accident, and Reducing Blood Utilization in Cardiac Surgery
March 15, 2019
Drugs and Devices The US Food and Drug Administration (FDA) announced that the indications for the MitraClip™, made by Abbott, have been expanded to include secondary mitral regurgitation.
February 22, 2019
Patient Care and General Interest
November 14, 2018
Thornblade and colleagues endeavored to develop and validate a model that would predict the 2-year risk of recurrence in patients with completely resected node-negative non-small cell lung cancer (NSCLC). Improved recurrence prediction could direct selective use of adjuvant therapy and surveillance imaging in these patients.
More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study
September 26, 2018
Using the National Cancer Database, the effect of the timing of computed tomography (CT) surveillance after resection of non-small cell lung cancer on survival was investigated. Survival was similar for patients undergoing CTs every three months or every six months compared to those undergoing annual surveillance CTs. More frequent imaging also had
September 25, 2018
A seismic shift occurred today when the NELSON screening trial results were presented at the IASLC 19th World Conference on Lung Cancer (
September 25, 2018
This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death.